Clinical Trial Update: A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating ARI-3037MO for hepatic fat metabolism in patients with dysglycemia and hepatic steatosis (nonalcoholic steatohepatitis) is u…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• ARI-3037MO

Snippet

Sponsor: Arisaph Pharmaceuticals Inc | Conditions: Nonalcoholic Steatohepatitis | Phase 2 | Status: UNKNOWN